Financial reports
10-K
2023 FY
Annual report
27 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-K/A
2022 FY
Annual report (amended)
16 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
15 May 23
ARS
2022 FY
Annual report to shareholders
5 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
18 Apr 24
8-K/A
Departure of Directors or Certain Officers
2 Apr 24
8-K
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA
7 Feb 24
8-K
Entry into a Material Definitive Agreement
1 Feb 24
8-K
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
16 Jan 24
8-K
Inhibikase Therapeutics Issues a Letter to Shareholders and Comments on Recent Trading Activity
20 Sep 23
8-K
Other Events
17 Jul 23
8-K
Inhibikase Therapeutics Announces a 1-for-6 Reverse Stock Split
29 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 23
8-K
Regulation FD Disclosure
22 Mar 23
Registration and prospectus
S-1/A
IPO registration (amended)
25 Apr 24
S-1
IPO registration
19 Apr 24
424B5
Prospectus supplement for primary offering
1 Feb 24
424B3
Prospectus supplement
4 Apr 23
POS AM
Prospectus update (post-effective amendment)
31 Mar 23
424B3
Prospectus supplement
8 Feb 23
D
$4.20 mm in options / securities to be acquired, sold $4.20 mm, 1 investor
7 Feb 23
S-1
IPO registration
1 Feb 23
424B5
Prospectus supplement for primary offering
27 Jan 23
424B5
Prospectus supplement for primary offering
16 May 22
Proxies
PRE 14A
Preliminary proxy
15 Apr 24
DEFA14A
Additional proxy soliciting materials
12 May 23
DEF 14A
Definitive proxy
5 May 23
PRE 14A
Preliminary proxy
21 Apr 23
DEFR14A
Revised proxy
22 Jun 22
DEFA14A
Additional proxy soliciting materials
3 May 22
DEF 14A
Definitive proxy
2 May 22
PRE 14A
Preliminary proxy
21 Apr 22
DEFA14A
Additional proxy soliciting materials
30 Apr 21
DEF 14A
Definitive proxy
30 Apr 21
Other
EFFECT
Notice of effectiveness
5 Apr 23
EFFECT
Notice of effectiveness
8 Feb 23
CORRESP
Correspondence with SEC
3 Feb 23
UPLOAD
Letter from SEC
3 Feb 23
EFFECT
Notice of effectiveness
14 Feb 22
CORRESP
Correspondence with SEC
9 Feb 22
UPLOAD
Letter from SEC
9 Feb 22
EFFECT
Notice of effectiveness
16 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
CORRESP
Correspondence with SEC
11 Jun 21
Ownership